(b)(4).Incorrect anatomy.Evaluation summary: the device was returned, inside a non-abbott guiding catheter, for evaluation and the reported difficulty to remove was confirmed.The reported failure to cross and resistance could not be confirmed as it was based on case circumstances.Based on visual, dimensional and functional analysis of the returned device, there is no indication of a product deficiency.A review of the lot history record revealed no non-conformances.A query of the electronic complaint handling database revealed no other similar incidents reported from this lot.It was reported that the herculink elite was being used to treat the proximal mesenteric artery.It should be noted that the herculink elite stent system instructions for use states: the rx herculink elite biliary stent system is intended for palliation of malignant strictures in the biliary tree.In this case, it could not be determined if the off-label use caused or contributed to the reported difficulties.Based on the information reviewed, there is no indication of a product deficiency.
|
(b)(4).It was reported that the herculink elite was being used to treat the proximal mesenteric artery.It should be noted that the herculink elite stent system instructions for use states: the rx herculink elite renal stent system is indicated for use in patients with atherosclerotic disease of the renal arteries following sub-optimal percutaneous transluminal renal angioplasty (ptra) of a de novo or restenotic atherosclerotic lesion (15 mm in length) located within 10 mm of the renal ostium and with a reference vessel diameter of 4.0 - 7.0 mm.In this case, it could not be determined if the off-label use caused or contributed to the reported difficulties.Based on the information reviewed, there is no indication of a product deficiency.
|